Creative Medical Tech Gains $4.2M in Warrant Exercise Deal
Creative Medical Technology secured approximately $4.2 million in gross proceeds through the immediate exercise of 1,116,136 previously issued, registered...
Jon Napitupulu
Wave’s Surging Obesity Drug Shows Promising Trial Results
Single-dose WVE-007 reduced circulating Activin E by 56% at 75 mg, 75% at 240 mg, and 85% at 400...
Wave Life Sciences Sees Positive Data for Obesity Drug WVE-007
Wave reported dose-dependent, single-dose reductions in circulating Activin E at day 29 in its INLIGHT obesity study: 85% at...
Tectonic’s TX45 Shows Positive Data in Phase 1b PH Trial
TX45 produced acute, directionally favorable hemodynamic and echocardiographic changes in PH-HFrEF after a single intravenous dose: pulmonary capillary wedge...
Immuron’s Latest Clinical Trial Update: A New Perspective
No new efficacy results were released. The Uniformed Services University Phase 2 traveler’s diarrhea field study of Travelan (n=851;...
Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025
Olema will bring a trial‑in‑progress poster for its Phase 3 OPERA‑02 study to SABCS, detailing a randomized, double‑blind comparison...
BioCardia’s Pivotal Heart Failure Trial Enrolls First Patient
In BioCardia’s earlier CardiAMP-HF study, the composite endpoint of all-cause death, nonfatal major adverse cardiac events, and a validated...
PDS Biotech to Present New Cancer Therapy Data at SITC 2025
PDS Biotechnology’s National Cancer Institute collaborators will deliver three presentations at SITC 2025, headlined by a rapid oral on...
Breakthrough Oral Semaglutide Pill Shows Preclinical Promise
Preclinical data to be presented at ObesityWeek 2025 indicate that Rani Therapeutics’ oral semaglutide candidate (RT-116), delivered via the...
Ultragenyx Doses First Patient in New Angelman Syndrome Study
Ultragenyx has fully randomized 129 patients aged 4–17 with full maternal UBE3A gene deletion in the global Phase 3...